金属硫蛋白在大肠癌中的研究进展

doi:10.11904/j.issn.1002-3070.2021.06.010

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (6): 538-541.doi: 10.11904/j.issn.1002-3070.2021.06.010

金属硫蛋白在大肠癌中的研究进展

赵轩¹, 李国东¹ 综述, 刘明² 审校

1.哈尔滨医科大学附属第四医院(哈尔滨市 150001);
2.哈尔滨医科大学附属第二医院

收稿日期:2020-12-08 修回日期:2021-03-02 出版日期:2021-12-28 发布日期:2021-12-17
通讯作者: 刘明,E-mail:Mliu35@aliyun.com
作者简介:赵轩,男,(1995-),硕士研究生,从事消化道肿瘤的研究。
基金资助:
黑龙江省自然科学基金-联合引导项目(编号:LH2020H066)

Research progress of metallothionein in colorectal cancer

ZHAO Xuan¹, LI Guodong¹, LIU Ming²

1. The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China;
2. The Second Affiliated Hospital of Harbin medical University

Received:2020-12-08 Revised:2021-03-02 Online:2021-12-28 Published:2021-12-17

摘要/Abstract

摘要： 金属硫蛋白(Metallothionein,MTs)是一种小蛋白,富含半胱氨酸。MTs在人体内主要分为四个亚型(MT1、MT2、MT3、MT4)。MTs的主要功能是清除自由基和参与重金属的解毒和稳态,同时具有抗氧化的特性。相关研究发现MTs可参与DNA的损伤修复,并且参与肿瘤的发生发展,与肿瘤细胞的耐药性相关。本文将对MTs在大肠癌中的研究进展做一综述。

关键词: 大肠癌, 金属硫蛋白, 进展

Abstract: Metallothionein(MTs)is a small protein,rich in cysteine.MTs is mainly divided into four subtypes in the human body(MT1,MT2,MT3 and MT4).The main function of MTs is to scavenge free radicals and participate in the detoxification and homeostasis of heavy metals,resulting from antioxidant properties.Recent studies have found that MTs can participate in the repair of DNA damage,and participate in the occurrence and development of tumors,and are related to the drug resistance of tumor cells.This article will review the research progress of MTs in colorectal cancer.

Key words: Colorectal cancer, Metallothionein, Progress

中图分类号:

R735.3

赵轩, 李国东, 刘明. 金属硫蛋白在大肠癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 538-541.

ZHAO Xuan, LI Guodong, LIU Ming. Research progress of metallothionein in colorectal cancer[J]. Journal of Practical Oncology, 2021, 35(6): 538-541.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/538

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Keum N,Giovannucci E.Global burden of colorectal cancer:emerging trends,risk factors and prevention strategies[J].Nat Rev Gastroenterol Hepatol,2019,16(12):713-732.
3 Brenner H,Kloor M,Pox CP.Colorectal cancer[J].Lancet,2014,383(9927):1490-1520.
4 Moleirinho A,Carneiro J,Matthiesen R,et al.Gains,losses and changes of function after gene duplication:study of the metallothionein family[J].PLoS One,2011,6(4):e18487.
5 Klaassen CD,Liu J,Diwan BA.Metallothionein protection of cadmium toxicity[J].Toxicol Appl Pharmacol,2009,238(3):215-220.
6 Kumari MV,Hiramatsu M,Ebadi M.Free radical scavenging actions of metallothionein isoforms I and II[J].Free Radic Res,1998,29(2):93-101.
7 Arriaga JM,Levy EM,Bravo AI,et al.Metallothionein expression in colorectal cancer:relevance of different isoforms for tumor progression and patient survival[J].Hum Pathol,2012,43(2):197-208.
8 Ferrario C,Lavagni P,Gariboldi M,et al.Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma[J].Lab Invest,2008,88(5):474-481.
9 Bizoń A,Jńdryczko K,Milnerowicz H.The role of metallothionein in oncogenesis and cancer treatment[J].Postepy Hig Med Dosw(Online),2017,71:98-109.
10 Janssen AM,van Duijn W,Ruit MM,et al.Metallothionein in human gastrointestinal cancer[J].J Pathol,2000,192(3):293-300.
11 Nagel WW,Vallee BL.Cell cycle regulation of metallothionein in human colonic cancer cells[J].Proc Natl Acad Sci U S A,1995,92(2):579-583.
12 Dutsch-Wicherek M,Sikora J,Tomaszewska R.The possible biological role of metallothionein in apoptosis[J].Front Biosci,2008,13:4029-4038.
13 Ostrakhovitch EA,Olsson PE,Jiang S,et al.Interaction of metallothionein with tumor suppressor p53 protein[J].FEBS Lett,2006,580(5):1235-1238.
14 Marikar FM,Jin G,Sheng W,et al.Metallothionein 2A an interactive protein linking phosphorylated FADD to NF-κB pathway leads to colorectal cancer formation[J].Chin Clin Oncol,2016,5(6):76.
15 Yan DW,Fan JW,Yu ZH,et al.Downregulation of metallothionein 1F,a putative oncosuppressor,by loss of heterozygosity in colon cancer tissue[J].Biochim Biophys Acta,2012,1822(6):918-926.
16 Morandi L,de Biase D,Visani M,et al.T([20])repeat in the 3′-untranslated region of the MT1X gene:a marker with high sensitivity and specificity to detect microsatellite instability in colorectal cancer[J].Int J Colorectal Dis,2012,27(5):647-656.
17 Arriaga JM,Bravo AI,Mordoh J,et al.Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells[J].Oncol Rep,2017,37(5):2633-2651.
18 Hishikawa Y,Kohno H,Ueda S,et al.Expression of metallothionein in colorectal cancers and synchronous liver metastases[J].Oncology,2001,61(2):162-167.
19 李世拥,于波,安萍.金属硫蛋白和FasL在大肠癌组织中表达及临床意义的研究[J].中华外科杂志,2005,43(17):18-20.
20 Kelley SL,Basu A,Teicher BA,et al.Overexpression of metallothionein confers resistance to anticancer drugs[J].Science,1988,241(4874):1813-1815.
21 Zhao Z,Zhang G,Li W.MT2A promotes oxaliplatin resistance in colorectal cancer cells[J].Cell Biochem Biophys,2020,78(4):475-482.
22 Arriaga JM,Greco A,Mordoh J,et al.Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy[J].Mol Cancer Ther,2014,13(5):1369-1381.
23 Tiwari R,Pandey SK,Goel S,et al.SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression[J].Oncogenesis,2015,4(8):e162.
24 Heger Z,Rodrigo MA,Krizkova S,et al.Metallothionein as a scavenger of free radicals-new cardioprotective therapeutic agent or initiator of tumor chemoresistance[J].Curr Drug Targets,2016,17(12):1438-1451.
25 Szelachowska J,Dziegiel P,Tarkowski R,et al.Therapeutic radiation induces different changes in expression profiles of metallothionein(MT)mRNA,MT protein,Ki 67 and minichromosome maintenance protein 3 in human rectal adenocarcinoma[J].Anticancer Res,2012,32(12):5291-5297.

[1]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[2]	胡洋, 张清媛. PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 184-187.
[3]	郭飘婷, 闵丽, 陈建军, 汪鑫, 倪思忆. 丹参酚酸B调控ROS抑制大肠癌细胞HCT-116增殖并促进其凋亡[J]. 实用肿瘤学杂志, 2020, 34(6): 504-510.
[4]	郭飘婷, 邹阳. LncRNA SOX2OT海绵吸附miR-34a促进SOX2表达增强大肠癌多药耐药[J]. 实用肿瘤学杂志, 2020, 34(5): 398-403.
[5]	郭永东, 靳晶, 李利敏, 贺宇彤. 分化拮抗非蛋白质编码RNA(DANCR)在常见恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 69-73.
[6]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[7]	许健, 詹月萍, 蒋元烨, 曹勤. α-常春藤皂苷的抗肿瘤药理作用研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 553-556.
[8]	李素素, 周春祥. NKT细胞对肝癌免疫应答的双向调控作用[J]. 实用肿瘤学杂志, 2019, 33(6): 540-543.
[9]	张谊微, 石晶, 刘宇鹏, 曹丽明, 胡付兰, 赵亚双. 外周血USP1基因甲基化与大肠癌预后风险的关系[J]. 实用肿瘤学杂志, 2019, 33(5): 420-424.
[10]	普睿, 朱琳, 夏婷婷, 毕皓然, 孙鸿儒, 黄浩, 张磊, 赵亚双. 外周血STAT1,STAT3基因启动子CpG岛甲基化状态与大肠癌预后关系的研究[J]. 实用肿瘤学杂志, 2019, 33(4): 346-351.
[11]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[12]	张宝综述, 郑志超校审. 进展期胃癌淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 78-81.
[13]	吴启润, 罗婷, 王鹏, 徐克. 营养支持方式在肿瘤晚期患者中应用现状及展望[J]. 实用肿瘤学杂志, 2018, 32(4): 381-384.
[14]	吕强, 陈洪生, 李国东, 魏九峰(综述), 刘明(审校). 肿瘤相关成纤维细胞在大肠癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 275-279.
[15]	庄敏敏, 张云艳. ICAM-1在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 82-86.

金属硫蛋白在大肠癌中的研究进展

Research progress of metallothionein in colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价